- Gilead and Amgen impress, Lilly and BMS depress in third quarter
- Results Preview: Amgen, the juggler
- SCOTUS mulls limiting class actions in Amgen case
- Unexpectedly positive Amgen reports 34% EPS growth with Q2 revenue up 13%
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.